Vericel (VCEL) Income from Continuing Operations (2010 - 2026)
Vericel recorded quarterly Income from Continuing Operations of 6373000.0 in Q1 2026, down 126.4% quarter-over-quarter from 24138000.0 in Q4 2025, and up 43.54% year-over-year from 4439821.27 in Q1 2025.
Vericel's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 6373000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 43.54% year-over-year to 6373000.0; the TTM figure through Mar 2026 stood at 22336000.0 (up 658.7% YoY), while the FY2025 annual figure was 16518000.0, up 59.41% from the prior year.
- Income from Continuing Operations came in at 6373000.0 for Q1 2026 at Vericel, down from 24138000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 24138000.0 in Q4 2025 to a low of 11288000.0 in Q1 2025.
- A 5-year average of 91235.29 and a median of 3855000.0 in 2024 frame the typical range for Income from Continuing Operations.
- On a YoY basis, Income from Continuing Operations climbed as much as 666.04% in 2025 and fell as far as 192.81% in 2025.
- Vericel's Income from Continuing Operations stood at 5922000.0 in 2022, then jumped by 119.4% to 12993000.0 in 2023, then surged by 52.44% to 19807000.0 in 2024, then gained by 21.87% to 24138000.0 in 2025, then slumped by 126.4% to 6373000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 6373000.0, 24138000.0, and 5100000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Vericel | 1.69 Bn | 1.55 Bn | 49.27 Mn | -6.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.37 Mn |
| Dec 31, 2025 | 24.14 Mn |
| Sep 30, 2025 | 5.10 Mn |
| Jun 30, 2025 | -529,000.00 |
| Mar 31, 2025 | -11.29 Mn |
| Dec 31, 2024 | 19.81 Mn |
| Sep 30, 2024 | -901,000.00 |
| Jun 30, 2024 | -4.67 Mn |
| Mar 31, 2024 | -3.86 Mn |
| Dec 31, 2023 | 12.99 Mn |
| Sep 30, 2023 | -3.66 Mn |
| Jun 30, 2023 | -5.02 Mn |
| Mar 31, 2023 | -7.48 Mn |
| Dec 31, 2022 | 5.92 Mn |
| Sep 30, 2022 | -6.58 Mn |
| Jun 30, 2022 | -8.96 Mn |
| Mar 31, 2022 | -7.09 Mn |
| Dec 31, 2021 | 4.54 Mn |
| Sep 30, 2021 | -4.93 Mn |
| Jun 30, 2021 | -3.79 Mn |
| Mar 31, 2021 | -3.29 Mn |
| Dec 31, 2020 | 12.22 Mn |
| Sep 30, 2020 | 3.62 Mn |
| Jun 30, 2020 | -8.27 Mn |
| Mar 31, 2020 | -4.71 Mn |
| Dec 31, 2019 | 9.53 Mn |
| Sep 30, 2019 | 3.48 Mn |
| Jun 30, 2019 | -19.77 Mn |
| Mar 31, 2019 | -2.88 Mn |
| Dec 31, 2018 | 7.81 Mn |
| Sep 30, 2018 | -1.49 Mn |
| Jun 30, 2018 | -4.61 Mn |
| Mar 31, 2018 | -4.75 Mn |
| Dec 31, 2017 | 1.99 Mn |
| Sep 30, 2017 | -4.35 Mn |
| Jun 30, 2017 | -2.82 Mn |
| Mar 31, 2017 | -9.88 Mn |
| Dec 31, 2016 | 1.27 Mn |
| Sep 30, 2016 | -6.47 Mn |
| Jun 30, 2016 | -4.99 Mn |
| Mar 31, 2016 | -1.99 Mn |
| Dec 31, 2015 | -4.95 Mn |
| Sep 30, 2015 | -4.87 Mn |
| Jun 30, 2015 | -2.26 Mn |
| Mar 31, 2015 | -4.56 Mn |
| Dec 31, 2014 | -2.33 Mn |
| Sep 30, 2014 | -8.02 Mn |
| Jun 30, 2014 | -8.52 Mn |
| Mar 31, 2014 | -4.64 Mn |
| Dec 31, 2013 | -4.92 Mn |
| Sep 30, 2013 | -3.64 Mn |
| Jun 30, 2013 | -5.23 Mn |
| Mar 31, 2013 | -7.16 Mn |
| Dec 31, 2012 | -7.61 Mn |
| Sep 30, 2012 | -8.28 Mn |
| Jun 30, 2012 | -9.28 Mn |
| Mar 31, 2012 | -8.56 Mn |
| Dec 31, 2011 | -7.83 Mn |
| Sep 30, 2011 | -7.43 Mn |
| Mar 31, 2011 | -6.24 Mn |
| Sep 30, 2010 | -5.83 Mn |
| Jun 30, 2010 | -5.12 Mn |